Registry of Lobbyists

Advanced Registry Search Results

Search Criteria

Search for novartis in registrations and monthly communication reports

Refine registrations results by

Status Type Subject matter Government institutions

If you would like to view a summary of the last 12 months for a lobbying activity, use the 12-Month Lobbying Activity Search

Registration (156)
Results: 1-50 | Export
  1. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Mark Vineis, Country President
    Registration: 37 of 37 (2024-01-01 to present)
    Posted: 2024-02-07
    Subject matter details: 9
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  2. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Pedro Ferreira, Country President
    Registration: 36 of 37 (2023-11-01 to 2024-01-01)
    Posted: 2023-12-07
    Subject matter details: 9
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 1
  3. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 31 of 32 (2023-10-11 to 2024-02-19)
    Posted: 2023-10-13
    Subject matter details: 13
    Government institutions: 14
    Communication techniques: 3
    Government funding: No
    Employees who lobby: 4
  4. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Pedro Ferreira, Country President
    Registration: 35 of 37 (2023-10-01 to 2023-11-01)
    Posted: 2023-10-16
    Subject matter details: 9
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 1
  5. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 30 of 32 (2023-04-26 to 2023-10-11)
    Posted: 2023-09-15
    Subject matter details: 13
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  6. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 29 of 32 (2023-04-24 to 2023-04-26)
    Posted: 2023-04-24
    Subject matter details: 13
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 5
  7. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 28 of 32 (2023-01-18 to 2023-04-24)
    Posted: 2023-01-18
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 5
  8. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Andrea Marazzi, Country President
    Registration: 34 of 37 (2023-01-13 to 2023-10-01)
    Posted: 2023-01-13
    Subject matter details: 9
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 1
  9. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Andrea Marazzi, Country President
    Registration: 33 of 37 (2022-10-05 to 2023-01-13)
    Posted: 2022-10-05
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  10. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 27 of 32 (2022-09-20 to 2023-01-18)
    Posted: 2022-09-20
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 4
  11. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 26 of 32 (2022-06-15 to 2022-09-20)
    Posted: 2022-06-15
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 4
  12. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Andrea Marazzi, Country President
    Registration: 32 of 37 (2022-06-01 to 2022-10-05)
    Posted: 2022-06-16
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  13. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 25 of 32 (2022-01-07 to 2022-06-15)
    Posted: 2022-01-07
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 4
  14. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 31 of 37 (2021-12-16 to 2022-06-01)
    Posted: 2021-12-16
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  15. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 24 of 32 (2021-06-03 to 2022-01-07)
    Posted: 2021-06-04
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 4
  16. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 30 of 37 (2021-05-03 to 2021-12-16)
    Posted: 2021-05-03
    Subject matter details: 11
    Government institutions: 12
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  17. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 29 of 37 (2020-09-14 to 2021-05-03)
    Posted: 2020-09-14
    Subject matter details: 11
    Government institutions: 11
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  18. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 23 of 32 (2020-08-06 to 2021-06-03)
    Posted: 2020-08-06
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 4
  19. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 22 of 32 (2020-06-08 to 2020-08-06)
    Posted: 2020-06-08
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  20. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 28 of 37 (2020-06-04 to 2020-09-14)
    Posted: 2020-06-05
    Subject matter details: 11
    Government institutions: 10
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  21. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 21 of 32 (2020-04-08 to 2020-06-08)
    Posted: 2020-04-09
    Subject matter details: 14
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 4
  22. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 20 of 32 (2020-03-25 to 2020-04-08)
    Posted: 2020-03-25
    Subject matter details: 13
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  23. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 19 of 32 (2020-03-11 to 2020-03-25)
    Posted: 2020-03-12
    Subject matter details: 12
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  24. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 27 of 37 (2020-02-14 to 2020-06-04)
    Posted: 2020-02-14
    Subject matter details: 11
    Government institutions: 10
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  25. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 18 of 32 (2019-12-17 to 2020-03-11)
    Posted: 2019-12-17
    Subject matter details: 12
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 5
  26. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 26 of 37 (2019-11-29 to 2020-02-14)
    Posted: 2019-11-29
    Subject matter details: 11
    Government institutions: 9
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  27. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 17 of 32 (2019-11-17 to 2019-12-17)
    Posted: 2019-11-18
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 5
  28. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 25 of 37 (2019-05-01 to 2019-11-29)
    Posted: 2019-06-20
    Subject matter details: 11
    Government institutions: 9
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  29. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Thea Discepola, Interim President
    Registration: 24 of 37 (2019-03-01 to 2019-05-01)
    Posted: 2019-04-12
    Subject matter details: 11
    Government institutions: 9
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  30. Alcon Canada Inc.
    Type: Consultant
    Lobbyist: CARL BALTARE, GLOBAL PUBLIC AFFAIRS
    Registration: 2 of 2 (2019-03-01 to 2020-01-14)
    Posted: 2019-03-04
    Subject matter details: 4
    Government institutions: 3
    Communication techniques: 2
    Government funding: No
  31. Alcon Canada Inc.
    Type: Consultant
    Lobbyist: Rhys Sandner, Global Public Affairs
    Registration: 1 of 4 (2019-03-01 to 2019-04-09)
    Posted: 2019-03-06
    Subject matter details: 4
    Government institutions: 3
    Communication techniques: 2
    Government funding: No
  32. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 16 of 32 (2019-01-09 to 2019-11-17)
    Posted: 2019-01-09
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 5
  33. Sandoz Canada Inc.
    Type: Consultant
    Lobbyist: Julian Worsley, Miller Thomson LLP
    Registration: 1 of 1 (2018-11-09 to 2020-04-03)
    Posted: 2018-11-28
    Subject matter details: 1
    Government institutions: 2
    Communication techniques: 2
    Government funding: No
  34. Alcon Canada Inc.
    Type: Consultant
    Lobbyist: CARL BALTARE, GLOBAL PUBLIC AFFAIRS
    Registration: 1 of 2 (2018-09-07 to 2019-03-01)
    Posted: 2018-09-11
    Subject matter details: 4
    Government institutions: 3
    Communication techniques: 2
    Government funding: No
  35. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 23 of 37 (2018-06-11 to 2019-03-01)
    Posted: 2018-06-12
    Subject matter details: 11
    Government institutions: 8
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  36. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 22 of 37 (2018-05-14 to 2018-06-11)
    Posted: 2018-05-17
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  37. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 15 of 32 (2018-04-09 to 2019-01-09)
    Posted: 2018-04-09
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 6
  38. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 21 of 37 (2018-03-20 to 2018-05-14)
    Posted: 2018-03-21
    Subject matter details: 13
    Government institutions: 6
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  39. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 14 of 32 (2018-01-23 to 2018-04-09)
    Posted: 2018-01-23
    Subject matter details: 12
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 7
  40. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 13 of 32 (2018-01-09 to 2018-01-23)
    Posted: 2018-01-09
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 6
  41. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 20 of 37 (2017-10-18 to 2018-03-20)
    Posted: 2017-10-19
    Subject matter details: 12
    Government institutions: 6
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  42. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 12 of 32 (2017-09-17 to 2018-01-09)
    Posted: 2017-09-18
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 6
  43. Novartis Pharmaceutical Canada Inc
    Type: Consultant
    Lobbyist: Elaine Larsen Wells, Capital Hill Group
    Registration: 1 of 1 (2017-08-10 to 2018-07-17)
    Posted: 2017-08-11
    Subject matter details: 1
    Government institutions: 12
    Communication techniques: 2
    Government funding: No
  44. Novartis Pharmaceutical Canada Inc
    Type: Consultant
    Lobbyist: DAVID ANGUS, The Capital Hill Group Inc.
    Registration: 1 of 1 (2017-08-09 to 2018-12-06)
    Posted: 2017-08-10
    Subject matter details: 1
    Government institutions: 12
    Communication techniques: 2
    Government funding: No
  45. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 19 of 37 (2017-05-01 to 2017-10-18)
    Posted: 2017-05-30
    Subject matter details: 12
    Government institutions: 6
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  46. Sandoz Canada Inc.
    Type: In-house Corporation
    Responsible officer: Michel Robidoux, President & Chief Executive Officer
    Registration: 11 of 32 (2017-04-18 to 2017-09-17)
    Posted: 2017-04-18
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 6
  47. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 18 of 37 (2017-03-21 to 2017-05-01)
    Posted: 2017-03-21
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  48. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 17 of 37 (2016-10-19 to 2017-03-21)
    Posted: 2016-10-21
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  49. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: CARL BALTARE, GLOBAL PUBLIC AFFAIRS
    Registration: 12 of 12 (2016-07-15 to 2020-01-14)
    Posted: 2016-07-21
    Subject matter details: 8
    Government institutions: 5
    Communication techniques: 2
    Government funding: No
  50. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 16 of 37 (2016-05-27 to 2016-10-19)
    Posted: 2016-05-27
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2

Monthly communication reports (84)
Results: 1-50 | Export
  1. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2024-02-29
    Posted: 2024-03-15
    Designated public office holders:
    • Rachel Blaney, Member of Parliament North Island Powell River | House of Commons
    Subject matters:
    • Health
    • Research and Development
  2. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2024-02-29
    Posted: 2024-03-15
    Designated public office holders:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons
    Subject matters:
    • Industry
    • Health
    • Science and Technology
  3. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2024-02-29
    Posted: 2024-03-15
    Designated public office holders:
    • Francesco Sorbara, Member of Parliment | House of Commons
    Subject matters:
    • Health
    • Industry
    • Research and Development
  4. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-12-07
    Posted: 2024-01-11
    Designated public office holders:
    • Ritu Banerjee, Assistant Deputy Minister, Director General's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Health
    • Science and Technology
    • Industry
  5. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-08
    Posted: 2023-12-15
    Designated public office holders:
    • Ritu Banerjee, Assistant Deputy Minister, Director General's Office | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Industry
    • Health
  6. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-07
    Posted: 2023-12-15
    Designated public office holders:
    • Jessica La Forge, Policy Advisor | Pacific Economic Development Canada (PacifiCan)
    • Gurjiven Sandhu, Director of Policy | Pacific Economic Development Canada (PacifiCan)
    Subject matters:
    • Science and Technology
    • Health
  7. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-06
    Posted: 2023-12-15
    Designated public office holders:
    • Francesco Sorbara, Member of Parliment | House of Commons
    Subject matters:
    • Health
    • Industry
  8. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-06
    Posted: 2023-12-15
    Designated public office holders:
    • Chandra Arya, Member of Parliament | House of Commons
    Subject matters:
    • Health
  9. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-06
    Posted: 2023-12-15
    Designated public office holders:
    • Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Health
  10. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-09-20
    Posted: 2023-10-16
    Designated public office holders:
    • Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)
    • Christopher Johnstone, Assistant Deputy minister | Health Canada (HC)
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Health
    • Industry
    • Research and Development
  11. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-08-17
    Posted: 2023-09-15
    Designated public office holders:
    • Mark Holland, Minister of Health | Health Canada (HC)
    Subject matters:
    • Science and Technology
    • Health
  12. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-06-23
    Posted: 2023-06-28
    Designated public office holders:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)
    Subject matters:
    • Health
    • Science and Technology
    • Research and Development
  13. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-06-22
    Posted: 2023-07-15
    Designated public office holders:
    • Jean-Sébastien Bock, Director of Policy, Minister's Office | Health Canada (HC)
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor, Minister's Office | Health Canada (HC)
    Subject matters:
    • Industry
    • Research and Development
    • Science and Technology
    • Health
  14. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-06-06
    Posted: 2023-07-15
    Designated public office holders:
    • Andy Fillmore, Member of Parliament | House of Commons
    Subject matters:
    • Health
    • Science and Technology
    • Industry
  15. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-25
    Posted: 2023-05-15
    Designated public office holders:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)
    Subject matters:
    • Science and Technology
    • Health
    • Industry
  16. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-25
    Posted: 2023-05-15
    Designated public office holders:
    • Bianca Hossain, Policy advisor, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Industry
    • Research and Development
    • Health
    • Science and Technology
  17. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-24
    Posted: 2023-05-15
    Designated public office holders:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Research and Development
    • Science and Technology
    • Health
  18. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-05
    Posted: 2023-05-15
    Designated public office holders:
    • Andy Fillmore, Member of Parliament | House of Commons
    Subject matters:
    • Science and Technology
    • Industry
    • Research and Development
    • Health
  19. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-03-10
    Posted: 2023-04-15
    Designated public office holders:
    • Jaxson Khan, Policy Advisor, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    • Pierre-Yves Bourque, Director of Operations, Ministers Office | Innovation, Science and Economic Development Canada (ISED)
    • Bianca Hossain, Policy advisor, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Health
  20. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-01-10
    Posted: 2023-02-15
    Designated public office holders:
    • Chris Zou, Policy Advisor, Office of Minister International Trade | Global Affairs Canada (GAC)
    Subject matters:
    • Health
    • Science and Technology
  21. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-01-04
    Posted: 2023-02-15
    Designated public office holders:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Health
    • Research and Development
  22. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-11-23
    Posted: 2022-12-15
    Designated public office holders:
    • Ashley Wright, Chief of Staff to the Minister, Minister's Office | Pacific Economic Development Canada (PacifiCan)
    • Chris Zou, Policy Advisor, Office of the Minister of International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)
    • Zachary Nixon, Chief of Staff to the Minister, Minister's Office International Trade | Global Affairs Canada (GAC)
    • Alexandre Boulé, Director Regional Affairs, Minister's Office | Canadian Heritage (PCH)
    • Camille Benoit-Blouin, Special Assistant, Policy, Minister's Office International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)
    • Jessie Pierre, Director of Policy, Ministers office | Federal Economic Development Agency for Southern Ontario (FedDev)
    Subject matters:
    • Health
    • Industry
    • Research and Development
    • Science and Technology
  23. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-09-29
    Posted: 2022-10-15
    Designated public office holders:
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    Subject matters:
    • Health
    • Industry
  24. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-07-21
    Posted: 2022-08-15
    Designated public office holders:
    • Seamus O'Regan, Minister of Labour | Employment and Social Development Canada (ESDC)
    Subject matters:
    • Health
    • Industry
  25. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-06-28
    Posted: 2022-07-04
    Designated public office holders:
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Industry
    • Health
    • International Trade
    • Science and Technology
    • Intellectual Property
  26. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-06-17
    Posted: 2022-07-04
    Designated public office holders:
    • Nancy Hamzawi, Assistant Deputy Minister | Health Canada (HC)
    • Stephen Lucas, Sous-ministre, Health Products and food branch | Health Canada (HC)
    Subject matters:
    • International Trade
    • Science and Technology
    • Health
    • Industry
    • Intellectual Property
  27. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Health
  28. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Adam Van Koeverden, Member of Parliament | House of Commons
    Subject matters:
    • Health
  29. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Luc Berthold, Député | House of Commons
    • Richard Lehoux, Member of Parliament | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    • Bernard Genereux, Member of Parliament | House of Commons
    • Jacques Gourde, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Health
  30. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Alexandre Boulerice, Member of Parliament | House of Commons
    Subject matters:
    • Health
    • Industry
  31. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Karl Sasseville, Deputy Chief of Staff, Minister's Office | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor, Minister's Office | Health Canada (HC)
    • Jamie Kippen, Chief of Staff, Minister's Office | Health Canada (HC)
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Jean-Sébastien Bock, Director of Policy, Minister's Office | Health Canada (HC)
    Subject matters:
    • Health
  32. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-30
    Posted: 2022-06-08
    Designated public office holders:
    • Eric Costen, Senior Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Industry
    • Science and Technology
    • Health
  33. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-03-25
    Posted: 2022-03-25
    Designated public office holders:
    • Sandenga Yeba, Conseiller principal, Politiques - bureau de Quebec, Cabinet du ministre | Health Canada (HC)
    Subject matters:
    • Health
  34. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-03-03
    Posted: 2022-04-16
    Designated public office holders:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons
    Subject matters:
    • Research and Development
    • Health
  35. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-02-14
    Posted: 2022-02-14
    Designated public office holders:
    • Jean-Sébastien Bock, Directeur des politiques, Santé Canada | Health Canada (HC)
    Subject matters:
    • Health
  36. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-01-27
    Posted: 2022-02-14
    Designated public office holders:
    • Luc Berthold, Député | House of Commons
    Subject matters:
    • Health
  37. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-12-09
    Posted: 2021-12-16
    Designated public office holders:
    • Jean-Yves Duclos, Ministre de la santé, Cabinet du ministre | Health Canada (HC)
    Subject matters:
    • Health
  38. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-12-06
    Posted: 2021-12-16
    Designated public office holders:
    • Luc Berthold, Député | House of Commons
    Subject matters:
    • Health
  39. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-12-01
    Posted: 2021-12-03
    Designated public office holders:
    • Miro Froehlich, Policy Advisor | Health Canada (HC)
    • Jean-Sebastien Bock, Director of Policy | Health Canada (HC)
    Subject matters:
    • Health
  40. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-11-22
    Posted: 2021-12-15
    Designated public office holders:
    • Marc Miller, Minister of Indigenous Services | Indigenous Services Canada (ISC)
    Subject matters:
    • Science and Technology
    • Industry
    • Health
  41. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-11-09
    Posted: 2021-12-15
    Designated public office holders:
    • François-Philippe Champagne, Minister of Innovation Science and Industry, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Health
    • Industry
  42. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-07-07
    Posted: 2021-08-16
    Designated public office holders:
    • Erin O'Toole, Member of Parliament, Official Leader of the Opposition | House of Commons
    Subject matters:
    • Science and Technology
    • Health
    • Research and Development
    • Industry
  43. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-06-21
    Posted: 2021-07-15
    Designated public office holders:
    • Erin O'Toole, Member of Parliament | House of Commons
    • Pierre Paul-Hus, Member of Parliament | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    Subject matters:
    • Research and Development
    • Industry
    • Science and Technology
    • Health
  44. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-06-04
    Posted: 2021-07-15
    Designated public office holders:
    • Luc Thériault, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Health
    • Science and Technology
  45. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-06-01
    Posted: 2021-07-15
    Designated public office holders:
    • Jordan Matte, Policy Advisor, Office of the Leader of the Opposition | House of Commons
    • Holly Duggan, Stakeholder Relations Advisor, Office of the Leader of the Opposition | House of Commons
    • Alexander MacDonald, Policy Advisor, Office of the Leader of the Opposition | House of Commons
    Subject matters:
    • Science and Technology
    • Industry
    • Health
  46. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-05-20
    Posted: 2021-06-15
    Designated public office holders:
    • Sabina Saini, Chief of Staff, Office of the Minister | Health Canada (HC)
    • Kathryn Nowers, Senior Policy Advisor, Office of the Minister | Health Canada (HC)
    Subject matters:
    • Research and Development
    • Science and Technology
    • Health
  47. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-05-19
    Posted: 2021-06-15
    Designated public office holders:
    • Joey Wong, Special Assistant to Jean Yip, MP | House of Commons
    • Jean Yip, Member of Parliament | House of Commons
    Subject matters:
    • Science and Technology
    • Health
    • Research and Development
  48. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-05-19
    Posted: 2021-06-15
    Designated public office holders:
    • Mike Lake, Member of Parliament | House of Commons
    • Nina Childs, Constituency Manager | House of Commons
    • Jaclyn Preece, Constituency Manager | House of Commons
    Subject matters:
    • Health
    • Science and Technology
    • Research and Development
  49. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-04-30
    Posted: 2021-05-15
    Designated public office holders:
    • Jean Yip, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Health
  50. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-04-29
    Posted: 2021-05-15
    Designated public office holders:
    • Alexandre Deslongchamps, Director of Operations, Minister's Office | Natural Resources Canada (NRCan)
    Subject matters:
    • Industry
    • Health

Date Modified: